Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Pulmonary long-term consequences of COVID-19 infections after hospital discharge

Jose-Ramon Blanco1, 2, *, Maria-Jesus Cobos-Ceballos3, 4, Francisco Navarro5, Isabel Sanjoaquin6, Francisco Arnaiz de las Revillas7, Enrique Bernal8, Luis Buzon-Martin9, Miguel Viribay10, Lourdes Romero11, Simona Espejo-Perez3, 11, Borja Valencia12, David Ibañez13, Diego Ferrer-Pargada14, Damian Malia15, Fernando-Gustavo Gutierrez-Herrero16, Julian Olalla5, Bernabe Jurado-Gamez3, 4, Javier Ugedo17

1) Servicio de Enfermedades Infecciosas, Hospital Universitario San Pedro, Logroño, La Rioja, Spain
2) Centro de Investigación Biomédica de La Rioja, Logroño, La Rioja, Spain
3) Instituto Matemáticos de Investigación Biomédica de Córdoba, Universidad de Córdoba, Spain
4) Servicio de Neumología, Hospital Universitario Reina Sofía, Córdoba, Spain
5) Servicio de Medicina Interna, Hospital Costal de Sol, Málaga, Spain
6) Servicio de Enfermedades Infecciosas, HCU Lozano Blesa, Zaragoza, Spain
7) Servicio de Enfermedades Infecciosas, H Universitario Marqués de Valdecilla, Santander, Spain
8) Sección de Enfermedades Infecciosas, Hospital General Universitario Reina Sofía de Murcia, Universidad de Murcia, Spain
9) Servicio de Medicina Interna, Hospital Universitario de Burgos, Spain
10) Vitro, Labora, Spain
11) Servicio de Radiología, Hospital Universitario Reina Sofía, Córdoba, Spain
12) Servicio de Neumología, Hospital Costal de Sol, Málaga, Spain
13) Servicio de Radiología, HCU Lozano Blesa, Zaragoza, Spain
14) Servicio de Neumología, H Universitario Marqués de Valdecilla, Santander, Spain
15) Servicio de Neumología, Hospital General Universitario Reina Sofía de Murcia, Spain
16) Servicio de Neumología, Hospital Universitario de Burgos, Spain
17) Servicio de Neumología, Hospital Universitario San Pedro, Logroño, La Rioja, Spain

ABSTRACT

Objectives: Coronavirus disease 2019 (COVID-19) survivors are reporting residual abnormalities after discharge from hospital. Limited information is available about this stage of recovery or the lingering effects of the virus on pulmonary function and inflammation. This study aimed to describe lung function in patients recovering from COVID-19 hospitalization and to identify biomarkers in serum and induced sputum samples from these patients.

Methods: Patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by a real-time PCR (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were recruited for this study. Each hospital screened their lists of discharged patients at least 45 days after symptom onset. SARS-CoV-2-infected patients were divided into mild/moderate and severe disease groups according to the severity of their symptoms during hospitalization. Patients’ epidemiological and medical histories, comorbidities, chronic treatments, and laboratory parameters were evaluated. Pulmonary function tests, the standardized 6-minute walk test (6MWT) and chest computed tomography (CT) were also performed. The levels of proteases, their inhibitors, and shed receptors were measured in serum and induced sputum samples.

Results: A total of 100 patients with respiratory function tests were included in this study. The median number of days after the onset of symptoms was 104 (IQR 89.25, 126.75). COVID-19 was severe in 47% of patients (47/100). CT was normal in 48% of patients (48/100). Lung function was normal forced expiratory...
volume in one second (FEV1) >80%, forced vital capacity (FVC) >80%, FEV1/FVC ≥0.7, and diffusing capacity for carbon monoxide (DLCO) >80% in 92% (92/100), 94% (94/100), 100% (100/100) and 48% (48/100) of patients, respectively. Multivariate analysis showed that a DLCO <80% (OR 5.92; 95%CI 2.28 –15.37; p < 0.0001) and a lower serum lactate dehydrogenase level (OR 0.98; 95%CI 0.97–0.99) were associated with the severe disease group of SARS-CoV-2 cases during hospital stay.

**Conclusions:** A diffusion deficit (DLCO <80%) was still present after hospital discharge and was associated with the most severe SARS-CoV-2 cases. *Jose-Ramon Blanco, Clin Microbiol Infect 2021;27:892*

© 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

**Introduction**

Approximately 104 million individuals worldwide have recovered from coronavirus disease 2019 (COVID-19) (https://coronavirus.jhu.edu/map.html). However, some survivors report persistent severe symptoms and organ dysfunction [1]. These symptoms might be, in part, a consequence of the cytokine storm suffered in the acute phase of the infection [2]. Previous studies have shown that higher levels of proinflammatory cytokine responses during the acute phase of other coronavirus infections—such as severe acute respiratory syndrome (SARS) [3] and the Middle East respiratory syndrome (MERS) [4]—were associated with severe lung disease. Unlike previous coronavirus diseases, COVID-19 does not seem to be just a respiratory affliction; rather, it is a viral infectious process involving multiple systems [5].

Residual lung abnormalities have been found in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1–3 months after discharge from hospital [6–9]. However, limited information is available about the serum inflammatory state during recovery from SARS-CoV-2 infection. Information on the impact of residual inflammation on the lungs is even rarer. Because the persistence of this inflammatory state in blood and sputum could have important prognostic implications, we performed this study.

**Methods**

**Participants**

This was a prospective study of patients older than 18 years of age who were admitted to different Spanish hospitals with laboratory-confirmed COVID-19 infection by real-time PCR (RT-PCR) assay for SARS-CoV-2. Each hospital screened their lists of discharged patients. These patients were interviewed by phone at least 45 days after symptom onset or cancer, chronic lung diseases, concurrent autoimmune diseases or cancer, chronic use of corticosteroids or immunosuppressive therapy, pregnancy, alcohol/drug abuse, or patients whose condition did not allow participation in this study. The study was approved by the Institutional Research Ethics Committees. All participants provided written informed consent.

Patients were divided into mild (mild and moderate) and severe groups according to the severity of their symptoms during their hospital stay. The mild group did not have pneumonia imaging, the moderate group showed pneumonia, and the severe group had dyspnoea, respiratory frequency ≥30/minute, blood oxygen saturation ≤93%, arterial oxygen partial pressure/fractional inspired oxygen ratio (PaO2/FIO2) <300, and/or lung infiltrates >50% of the lung field within 24–48 hours [10]. Patients requiring invasive mechanical ventilation (MV) were excluded because of the impact of MV on systemic inflammation [11].

Epidemiological and medical history, comorbidities, chronic treatments, and laboratory parameters were evaluated. Smoking status was determined from self-administered survey responses. Anthropometric measurements included body mass index (BMI). At least 45 days after symptom onset pulmonary function testing, standardized 6-minute walk tests (6MWT) [12], and chest computed tomography (CT) were performed. Lung function included forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), FEV1/FVC ratio and diffusion capacity of the lung for carbon monoxide (DLCO). Diffusion deficit was considered a DLCO <80% of the predicted value [13]. The 6MWT, a practical and simple test that provides a global measure of functional capacity, was performed in accordance with international recommendations [12]. Peripheral oxygen saturation (SpO2) was monitored using a handheld oximeter. ΔSpO2–6MWT was defined as the difference between the resting and nadir SpO2. The 6MWT distance was also evaluated [14]. CT was considered normal in the absence of ground-glass opacification, crazy-paving patterns, consolidation, or linear opacities [15].

The levels of biomarkers were measured in serum and induced sputum samples. Serum samples were obtained from blood drawn at a date close to the tests already described and stored at −80°C. Sputum was induced as previously described [16] and stored at −80°C. It was obtained, whenever possible, on the same day as the respiratory function tests. The concentrations of multiple proteases and their inhibitors (plasminogen activator inhibitor 1 (PAI-1), PAI-2, and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) and shed receptors (intracellular adhesion molecule 1 (ICAM-1), ICAM-3, osteoprotegerin (OPG)) were evaluated in serum and sputum samples. These parameters were analysed in duplicate employing commercially available ELISA kits. The lower detection limits are shown in Supplementary Material Table S1. All samples were tested individually (one sample per well), but samples from all groups were measured on the same plate. The hook effect—a state of antigen excess relative to the antibody probes—resulting in falsely lowered values was ruled out after analysing undiluted and diluted samples.

**Data analysis**

Categorical variables were reported as frequencies and proportions. Continuous variables with a normal distribution are presented as the mean (standard deviation, SD), and those with a non-normal distribution are presented as the median (interquartile range values (IQRs) p25, p75). To compare the demographic and clinical variables between groups, the χ² test or Fisher’s exact test was used for each categorical variable, as appropriate. For quantitative variables, the non-parametric Mann–Whitney U test was used.

Multivariate analysis was carried out using binary logistic regression with the forward conditional method, introducing DLCO (<80 versus ≥80%) as the dependent variable. Independent
variables were all variables that were statistically significant in the bivariate analysis or in clinical implications. The results of the multivariate model were adjusted, and we present the odds ratio and its 95% confidence interval (CI). Statistical significance was set at \( p < 0.05 \). Analyses were performed using SPSS 24.0 software (SPSS Inc., Chicago, IL, USA).

**Results**

A total of 108 patients were included in this study. Of the sample, 100 had adequate respiratory function tests. Most 69% were \( >50 \) years (69/100), 64% were male (64/100), and 90% were Caucasian (90/100). The median number of days after the onset of symptoms was 104 (IQR 89.25, 126.75). Common comorbidities included hypertension (25%, 25/100), diabetes mellitus (10%, 10/100), cardiovascular disease (4%, 4/100), and chronic kidney disease (2%, 2/100). Obesity (BMI \( \geq 30 \)) was present in 37% (37/100). Chronic therapy included use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (17%, 17/100), statins (12%, 12/100), and aspirin (3%, 3/100).

Since the SARS-CoV-2 outbreak there has been increasing concern about the potential risk of parenchymal fibrosis and lung function impairment. The most important factor is lung diffusion capacity \([17]\). Zhao et al. \([6]\) reported that 3 months after discharge of COVID-19 patients a high percentage of CT abnormalities (70.9%) and DLCO anomalies (16.4%) were still present in recovering patients. Other authors, such as Mo et al. \([7]\), reported that nearly a month after hospital discharge, regardless of the degree of COVID-19 severity, no significant differences in FEV1, FVC, or its ratio were observed. However, the DLCO value was significantly lower as the severity of the clinical picture increased (47.2% in total; 30.4% in mild illness and 84.2% in severe pneumonia). In this study, the authors included a small number of patients with previous pulmonary pathologies, one of the exclusion criteria of our study. Likewise, Frija-Masson et al. \([9]\) observed that more than half of patients with COVID-19 pneumonia, some of whom had respiratory comorbidities, exhibited abnormal lung function 1 month after symptom onset, without a clear relationship with pneumonia extent on chest CT. Huang et al. \([18]\) observed that 30 days after discharge from hospital, patients exhibited nearly significant differences in DLCO values (<80%), 42.5% in non-severe cases and

| Table 1 Patient characteristics among coronavirus disease 2019 (COVID-19) survivors according to diffusion capacity of the lung for carbon monoxide (DLCO) severity |
|-----------------|-----------------|-----------------|-----------------|
| **Age in years, mean (±SD) (n, 52)** | DLCO <80 | DLCO >80 | p |
| **Age >50 years, n (%)** | 54.98 ± 10.72 | 54.75 ± 9.83 | 0.911 |
| Male sex, n (%) | 34 (65.4) | 35 (72.9) | 0.416 |
| Caucasian, n (%) | 33 (63.5) | 31 (64.6) | 0.907 |
| Never smoker history, n (%) | 47 (90.4) | 43 (89.6) | 0.894 |
| **Comorbidities** | | | |
| Cardiovascular disease, n (%) | 4 (7.7) | 0 (0) | 0.119 |
| Hypertension, n (%) | 15 (28.8) | 10 (20.8) | 0.355 |
| Diabetes mellitus, n (%) | 7 (13.5) | 3 (6.4) | 0.324 |
| Chronic renal failure, n (%) | 2 (3.8) | 0 (0) | 0.496 |
| Chronic aspirin use, n (%) | 2 (3.8) | 1 (2.1) | 1.000 |
| Chronic statin use, n (%) | 8 (15.4) | 4 (8.3) | 0.362 |
| Chronic ACE/ARA-II use, n (%) | 9 (17.3) | 8 (16.7) | 0.932 |
| **COVID-19 data during hospitalization admission** | | | |
| Severe disease during hospital admission, n (%) | 34 (65.4) | 13 (27.1) | -0.0001 |
| Days of hospitalization, median (p25, p75) | 7.0 (5.0, 9.75) | 8.0 (6.0, 11.0) | 0.038 |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; ICAM, intracellular adhesion molecule; LDH, lactate dehydrogenase; OPG, osteoprotegerin; PAI, plasminogen activator inhibitor; TIMP, tissue inhibitor of matrix metalloproteinase; WBC, white blood cell count.
75.6% in severe cases (p < 0.053). In that study, patients with a previous history of pulmonary resection, neurological disease, or mental illness were excluded. In our study, DLCO findings were close to those observed by Mo et al. [7] and Huang et al. [18], while the CT findings were clearly better than those reported by Zhao et al. [6].

After the 2003 outbreak of SARS, survivors evaluated within 3 months of discharge showed that lung fibrotic changes occurred mostly in severely ill patients [19]. These same authors also observed that when assessing lung fibrotic changes, DLCO scores are more sensitive than chest radiography and/or high-resolution CT. These results are similar to those of our group. During the follow-up of SARS patients, abnormal CT (30%) and impaired DLCO function (15.5%) [20] were still present 6 months later. These authors also observed significant impairment in DLCO function (23.7%) 1 year after illness onset [21]. All these data suggest that some of the recovered COVID-19 patients will have significantly impaired lung function months after discharge.

Contrary to our expectations, LDH levels were significantly lower in patients with DLCO abnormalities (<80%). However, serum LDH is a sensitive, burdensome marker for cell injury [22]. One of the reasons could be that its levels vary in multiple circumstances (cell damage related to ischaemia, exposure to bacterial toxins, chemical poisoning, etc.), which is why serum LDH is difficult to use as a valid biomarker of lung damage or inflammation [22]. However, some authors have observed that LDH (cut-off value of 344.5 U/L) could be a predictive factor for early recognition of lung injury and severe COVID-19 cases [23]. These levels are clearly higher than those presented by our patients.

Although the 6MWT is a validated clinical test designed for use in adults with chronic respiratory disease [24,25], it could be an appropriate test to triage COVID-19 patients. In fact, Huang et al. [18] observed that severe SARS-CoV-2 patients had a greater 6MWT decline than non-severe patients. In our study, although the distances covered were significantly lower in patients with abnormal DLCO values, these differences disappeared after multivariate analysis.

Sputum induction is a non-invasive method that has been employed to evaluate bronchial inflammation in patients with asthma and other respiratory diseases [26]. This technique allows us to obtain small sputum macrophages that exhibit features of highly active inflammatory cells that could be used to evaluate inflammatory biomarkers [27]. In our study we considered it necessary to measure both markers in serum and in induced sputum because it was unlikely that analysis of serum markers alone would be enough to reflect an ongoing residual pulmonary inflammatory state. For example, Ropcke et al. [28] observed few and weak correlations between lung and serum markers in chronic obstructive pulmonary disease patients. Contrary to our expectations, we observed that none of the parameters analysed correlated with the alterations observed in pulmonary diffusion.

Multiple mechanisms of lung injury in COVID-19 patients have been described [29]. However, the mechanisms underlying the potential long-term pathogenicity of SARS-CoV-2 have not been studied thus far. For this reason, multiple biomarkers implicated in pulmonary fibrosis were evaluated [30,31]. To the best of our knowledge, they have not been evaluated in COVID-19 patients. Although PAI levels are significantly elevated in the plasma of hospitalized COVID-19 patients [32], and mRNA levels are higher in the lungs of COVID-19 patients than in those of uninfected or influenza patients [33], we did not find differences, perhaps because we analysed a non-acute phase. Finally, ICAM (which is also elevated in the sera of patients with pulmonary fibrosis [34]), in the context of the first transcriptomic analysis performed to date on SARS-CoV-2 and IPF, showed that it has a relevant role in both processes [35]. In our study we found no significant differences. Thus, we need to continue studying biomarkers that might identify the potential progression of lung damage.

Our study has some limitations. First, this study included a small number of patients, so results should be interpreted with caution. Statistical non-significance may not rule out differences between severe and mild/moderate cases. In the same way, there was no comparison group (control group). However, that was not the aim of the study because we focused on SARS-CoV-2 survivors. Second, at the time we planned this study, there was a deep concern about the potential sequelae of this infection and whether any early intervention was required. Third, although it has been suggested that the viral load of SARS-CoV-2 could be a useful marker for assessing disease severity and prognosis [36], we did not include it by assuming that this was related to the severity of the clinical picture. Fourth, although the use of corticosteroids or other immunosuppressive agents was not evaluated, their use could be supposed based on the severity of the disease. This study was carried out before these agents were considered a therapeutic option for COVID-19 patients. Finally, this study has strengths, such as the decision to include the non-invasive induced sputum procedure.

In summary, this study has shown that a high proportion of severely affected COVID-19 patients show impairment in DLCO measurements in the first few months after symptom onset. Although its long-term impact is still unknown, DLCO could be considered a useful tool to identify individuals at risk for pulmonary sequelae. It will be necessary to follow these patients for
longer periods of time to detect needs and appropriately manage potential lung damage.

Transparency declaration

The authors declare that they have no conflicts of interest. This work was supported by the “Convocatoria de expresiones de interés para la financiación de proyectos de investigación sobre el SARS-CoV-2 y la enfermedad COVID” from the Instituto de Salud Carlos III (Project CV20/00401).

Acknowledgements

We thank all the patients and their families involved in this study, as well as numerous doctors, nurses, and people working together to fight against the SARS-CoV-2. Other collaborators in this project: HU San Pedro (Logroño): L. Perez-Martinez, M.A. Martinez, M.F. Espada; HCU Lozano Blesa (Zaragoza): P. Crusells, S. Letona, J.M. Guzman, L. Anoro, E. Garcia, M.M. Rivas, A. Prados, J. Izquierdo, R. Pinilla, A. Lainez, R. García, C. Gonzalez, P. Sanchez; HU Reina Sofia de Murcia: C. Alcade, A. Alcaraz, M.J. Alcaraz, A. Cano, A. Munoz; HU Burgos: M.S. Serrano, E. Reguero, E. Araujo.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2021.02.019.

References

[1] Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA 2020. https://doi.org/10.1001/jama.2020.19719.
[2] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–4.
[3] Zhang Y, Li J, Zhang Y, Wu L, Yu X, Zhang W, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun 2004;72: 4410–5.
[4] Mahalawai WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine 2018;108:4–8.
[5] Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091. https://doi.org/10.1136/bmj.m1091.
[6] Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine 2020;25:100463.
[7] Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J 2020;55:2001217. https://doi.org/10.1183/13993003.01217-2020.
[8] Wei J, Yang H, Lei P, Fan B, Qiu Y, Zeng B, et al. Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge. J Xray Sci Technol 2020;28:383–9.
[9] Frja-Masson J, Debray MP, Gilbert M, Lesure FX, Traval F, Borie R, et al. Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection. Eur Respir J 2020;56:2001754.
[10] Report of the WHO-China Joint Mission on Coronavirus disease. https://www. who.int/docs/default-source/coronaviruswho/who-china-joint-mission-on-covid-19-final-report-2019.
[11] Hennus MP, van Vught AJ, Brabander M, Brus F, Jansen NJ, Bont JJ. Mechanical ventilation drives inflammation in severe viral bronchiolitis. PloS One 2013;8: e58305.
[12] ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–7.
[13] Pellegrino R, Viegel G, Brusasco V, Crape RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948–68.
[14] Wegrzynowska-Teodorczyk K, Rudzinska E, Lazaroczky M, Nowakowska K, BanaÅski W, Poniakowski P, et al. Distance covered during a six-minute walk test predicts long-term cardiovascular mortality and hospitalisation rates in men with systolic heart failure: an observational study. J Physiother 2013;59: 177–87.
[15] Dng X, Xu J, Zhou J, Long Q. Chest CT findings of COVID-19 pneumonia by duration of symptoms. Eur Radiol 2020;127:109099.
[16] Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing, Eur Respir J Suppl 2002;37:15–2s.
[17] Torres-Castro R, Vasconcello-Castillo L, Alasina-Restoy X, Solis-Navarro L, Burgos F, Puppio H, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology 2020;25: 30245–52. 52S31-0437.
[18] Huang Y, Tan C, Wu J, Chen M, Wang Z, Luo L, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res 2020;21:163.
[19] Xue L, Liu Y, Xiao F, Tian Q, Fan B, Zhao H, et al. Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge. Chest 2005;127:2119–24.
[20] Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax 2005;60: 401–9.
[21] Hui DS, Wong KT, Ko PW, Tam LS, Chan DP, Woo J, et al. The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors. Chest 2005;28:2347–61.
[22] Thomeer M, Gruiters JC, Wuyts WA, Willems S, Desmedt MC. Clinical use of biomarkers of survival in pulmonary fibrosis. Respir Res 2010;11:89.
[23] Han Y, Zhang H, Mu S, Wei W, Jin C, Tong C, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging (Albany NY) 2020;12:11245–58.
[24] Singh SJ, Puhar MA, Andrianopoulos V, Hernandes NA, Mitchell KE, Hiji C, et al. An official systematic review of the European Respiratory Society/ American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J 2014;44:1447–78.
[25] Holland AE, Spruit MA, Troosters T, Puhar MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014;44:1428–46.
[26] Eickmeier O, Huebner M, Herrmann E, Zissler U, Boer PC, et al. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine 2010;50:152–7.
[27] Frankenberger M, Menzel M, Bertz R, Kassner G, Weber N, Kohlhaufl M, et al. Characterization of a population of small macrophages in induced sputum of patients with chronic obstructive pulmonary disease and healthy volunteers. Clin Exp Immunol 2004;138:507–16.
[28] Ropcke S, Holz O, Lauer G, Muller M, Rittinghausen S, Ernst P, et al. Repeat- ability and relationship of potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum. PloS One 2012;7:e46207.
[29] Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol 2020;92: 491–4.
[30] Habibie H, Putri KSSS, Boorsma CE, Brass DM, Heukels P, Wijesnike M, et al. Osteoprotegerin is elevated in pulmonary fibrosis and associates with IPP expression. bioRxiv 2020. https://doi.org/10.1101/2020.12.02.408062.
[31] Pardo A, Selman M, Kaminski N. Approaching the degradation in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008;40:1141–55.
[32] Goshua G, Pine AB, Meszlish ML, Chang CH, Zhang H, Bahel P, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 2020;7:e575–82.
[33] Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020;383:120–8.
[34] Tsotsou PC, Gourgoulianis KI, Petinaki E, Mpaka M, Efremidou S, Maniatis A, et al. ICAM-1, ICAM-2 and ICAM-3 in the sera of patients with idiopathic pulmonary fibrosis. Immunology 2004;28:359–64.
[35] Taz TA, Ahmed K, Paul BK, Kawsar M, Aktar N, Mahmud SMH, et al. Network- based identification genetic effect of SARS-CoV-2 infections to Idiopathic pulmonary fibrosis (IPF) patients. Brief Bioinform 2020. https://doi.org/ 10.1093/bib/bbaa235.
[36] Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020;20:656–7.